Injectable Thermoresponsive Hybrid Hydrogel for Localized Chemo‐Immunotherapy via Co‐Delivery of Doxorubicin‐Loaded Tumor‐Derived Exosomes and Immunoadjuvants
Advanced Healthcare Materials · 2026-09 · 15 (33)
DOI: 10.1002/adhm.71506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 30.07.2026. Verfasst von Yunan Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China. Hauptthemen laut MEDLINE: Doxorubicin, Exosomes, Hydrogels, Adjuvants, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The therapeutic efficacy of melanoma immunochemotherapy is severely limited by insufficient intratumoral drug retention, systemic toxicity, and immunosuppressive tumor microenvironment (TME). Thus, we developed a single‐dose injectable localized chemo‐immunotherapy platform that enables sustained tumor‐restricted delivery and synergistic immune remodeling. This hybrid system integrates doxorubicin‐loaded tumor‐derived exosome‐coated hollow mesoporous silica nanoparticles (DeH) with a mannose‐modified β‐cyclodextrin‐polyethyleneimine carrier co‐delivering dual Toll‐like receptor agonists (RC‐MCP) within a thermoresponsive polypeptide hydrogel (mPEG‐ b ‐PELG). The biomimetic exosome coating provides an exosome‐sheathed nanostructure and amplifies doxorubicin‐induced immunogenic cell death. Mannose‐mediated targeting facilitates preferential uptake by antigen‐presenting cells and enhances endosomal Toll‐like receptor signaling, leading to robust dendritic cell maturation. Following intratumoral injection, the hydrogel undergoes in situ sol‐gel transition to form a stable drug depot, enabling sustained and coordinated release while minimizing systemic exposure. As a result, a single intratumoral administration elicits potent antitumor immune responses, significantly suppresses tumor growth, alleviates TME immunosuppression, and exhibits favorable biocompatibility in murine melanoma model. Collectively, this work presents a rationally designed single‐dose localized chemo‐immunotherapy strategy for melanoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, China.
ORCID-Profile: Chaoliang He
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yuan, Y., Wu, Y., Yang, J., Li, F., Huang, R., Cheng, Q., Rong, Y., & He, C. (2026). Injectable Thermoresponsive Hybrid Hydrogel for Localized Chemo‐Immunotherapy via Co‐Delivery of Doxorubicin‐Loaded Tumor‐Derived Exosomes and Immunoadjuvants. Advanced Healthcare Materials, 15(33). https://doi.org/10.1002/adhm.71506
Vancouver
Yuan Y, Wu Y, Yang J, Li F, Huang R, Cheng Q, et al. Injectable Thermoresponsive Hybrid Hydrogel for Localized Chemo‐Immunotherapy via Co‐Delivery of Doxorubicin‐Loaded Tumor‐Derived Exosomes and Immunoadjuvants. Advanced Healthcare Materials. 2026;15(33). doi:10.1002/adhm.71506
BibTeX
@article{Yuan2026,
author = {Yuan, Yunan and Wu, Yijun and Yang, Jiaxuan and Li, Fujiang and Huang, Ruonan and Cheng, Qian and Rong, Yan and He, Chaoliang},
title = {Injectable Thermoresponsive Hybrid Hydrogel for Localized Chemo‐Immunotherapy via Co‐Delivery of Doxorubicin‐Loaded Tumor‐Derived Exosomes and Immunoadjuvants},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {33},
doi = {10.1002/adhm.71506}
}
EUVIMED